David P. Schenkein's most recent trade in Prime Medicine Inc was a trade of 45,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Aug. 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prime Medicine Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2025 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | David P. Schenkein | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Aug 2025 | 45,000 | 0 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | David P. Schenkein | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Aug 2025 | 39,062 | 0 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2025 | 39,062 | 39,062 | - | - | Stock Option (right to buy) | |
| Prime Medicine Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 18,111 | 18,111 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 6,037 | 15,257 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,958 | 1,958 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 166 | 448 (0%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | David P. Schenkein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2024 | 47,165 | 0 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | David P. Schenkein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.00 per share. | 11 Nov 2024 | 47,165 | 68,661 (0%) | 0% | 18 | 848,970 | Common Stock |
| Denali Therapeutics Inc | David P. Schenkein | Director | Sale of securities on an exchange or to another person at price $ 32.87 per share. | 11 Nov 2024 | 32,312 | 9,220 (0%) | 0% | 32.9 | 1,062,095 | Common Stock |
| Denali Therapeutics Inc | David P. Schenkein | Director | Sale of securities on an exchange or to another person at price $ 32.09 per share. | 11 Nov 2024 | 27,129 | 41,532 (0%) | 0% | 32.1 | 870,570 | Common Stock |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 13 Jun 2024 | 3,388 | 126,242 (0%) | 0% | 0 | Common stock | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | ||
| Prime Medicine Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,901 | 17,901 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 5,967 | 21,496 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | P. David Schenkein | Director | 27 Feb 2024 | 57,471 | 0 | - | - | Stock option (right to buy) | ||
| Agios Pharmaceuticals Inc | Schenkein P. David | Director | 27 Feb 2024 | 57,471 | 122,854 (0%) | 0% | 34.9 | 2,005,163 | Common stock | |
| Agios Pharmaceuticals Inc | David Schenkein P. | Director | 27 Feb 2024 | 57,471 | 180,325 (0%) | 0% | 31.6 | 1,818,382 | Common stock | |
| Agios Pharmaceuticals Inc | Schenkein David P. | Director | 27 Feb 2024 | 11,858 | 134,712 (0%) | 0% | 31.6 | 375,187 | Common stock | |
| Agios Pharmaceuticals Inc | Schenkein David P. | Director | 27 Feb 2024 | 11,858 | 57,471 | - | - | Stock option (right to buy) | ||
| Agios Pharmaceuticals Inc | P. Schenkein David | Director | 27 Feb 2024 | 11,858 | 122,854 (0%) | 0% | 33.6 | 398,429 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 23 Feb 2024 | 47,731 | 89,740 | - | - | Stock option (right to buy) | ||
| Agios Pharmaceuticals Inc | P. Schenkein David | Director | 23 Feb 2024 | 47,731 | 122,854 (0%) | 0% | 33.1 | 1,577,510 | Common stock | |
| Agios Pharmaceuticals Inc | P. Schenkein David | Director | 23 Feb 2024 | 47,731 | 170,585 (0%) | 0% | 31.6 | 1,510,209 | Common stock | |
| Agios Pharmaceuticals Inc | David Schenkein P. | Director | 23 Feb 2024 | 20,411 | 143,265 (0%) | 0% | 31.6 | 645,804 | Common stock | |
| Agios Pharmaceuticals Inc | P. David Schenkein | Director | 23 Feb 2024 | 20,411 | 122,854 (0%) | 0% | 33.2 | 677,441 | Common stock | |
| Agios Pharmaceuticals Inc | P. David Schenkein | Director | 23 Feb 2024 | 20,411 | 69,329 | - | - | Stock option (right to buy) | ||
| Regeneron Pharma | Schenkein P. David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 508 | 508 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | P. David Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 42 | 282 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 21 Jun 2023 | 4,975 | 0 | - | - | Restricted stock unit | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 21 Jun 2023 | 4,975 | 122,854 (0%) | 0% | 0 | Common stock | ||
| Prime Medicine Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 39,062 | 39,062 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | ||
| Denali Therapeutics Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 12,649 | 12,649 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,216 | 15,529 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 03 Apr 2023 | 16,363 | 134,242 (0%) | 0% | 9.0 | 148,085 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 03 Apr 2023 | 16,363 | 117,879 (0%) | 0% | 22.9 | 373,895 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 03 Apr 2023 | 16,363 | 0 | - | - | Stock option (right to buy) | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 27 Mar 2023 | 20,000 | 137,879 (0%) | 0% | 9.1 | 181,000 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 27 Mar 2023 | 20,000 | 16,363 | - | - | Stock option (right to buy) | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 27 Mar 2023 | 20,000 | 117,879 (0%) | 0% | 22.2 | 443,000 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 13 Mar 2023 | 20,000 | 137,879 (0%) | 0% | 9.1 | 181,000 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 13 Mar 2023 | 20,000 | 36,363 | - | - | Stock option (right to buy) | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 13 Mar 2023 | 18,333 | 119,546 (0%) | 0% | 22.5 | 411,943 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 13 Mar 2023 | 1,667 | 117,879 (0%) | 0% | 22.7 | 37,874 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 27 Feb 2023 | 20,000 | 137,879 (0%) | 0% | 9.1 | 181,000 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 27 Feb 2023 | 20,000 | 56,363 | - | - | Stock option (right to buy) | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 27 Feb 2023 | 20,000 | 117,879 (0%) | 0% | 25.4 | 507,400 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 13 Feb 2023 | 20,000 | 137,879 (0%) | 0% | 9.1 | 181,000 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 13 Feb 2023 | 20,000 | 117,879 (0%) | 0% | 28.6 | 572,400 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 13 Feb 2023 | 20,000 | 76,363 | - | - | Stock option (right to buy) | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 30 Jan 2023 | 20,000 | 137,879 (0%) | 0% | 9.1 | 181,000 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 30 Jan 2023 | 20,000 | 96,363 | - | - | Stock option (right to buy) | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 30 Jan 2023 | 16,700 | 121,179 (0%) | 0% | 29.2 | 487,974 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 30 Jan 2023 | 3,300 | 117,879 (0%) | 0% | 29.9 | 98,604 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 17 Jan 2023 | 20,000 | 116,363 | - | - | Stock option (right to buy) | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 17 Jan 2023 | 20,000 | 137,879 (0%) | 0% | 9.1 | 181,000 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 17 Jan 2023 | 18,966 | 118,913 (0%) | 0% | 28.8 | 546,600 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 17 Jan 2023 | 1,034 | 117,879 (0%) | 0% | 29.5 | 30,493 | Common stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | ||
| Denali Therapeutics Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,959 | 17,959 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 5,986 | 11,313 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 20 May 2022 | 1,585 | 117,879 (0%) | 0% | 0 | Common stock | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 22 Feb 2022 | 2,775 | 0 | - | - | Restricted stock units | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 22 Feb 2022 | 2,775 | 117,052 (0%) | 0% | 0 | Common stock | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 22 Feb 2022 | 758 | 116,294 (0%) | 0% | 29.1 | 22,043 | Common stock | |
| Denali Therapeutics Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 6,222 | 6,222 | - | - | Stock Option (right to buy) | |
| Denali Therapeutics Inc | David P. Schenkein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 2,074 | 5,327 (0%) | 0% | 0 | Common Stock | |
| Denali Therapeutics Inc | David P. Schenkein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 3,253 | 0 | - | - | Restricted Stock Units | |
| Denali Therapeutics Inc | David P. Schenkein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 3,253 | 3,253 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 28 May 2021 | 1,686 | 0 | - | - | Restricted stock units | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 28 May 2021 | 1,686 | 114,277 (0%) | 0% | 0 | Common stock | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 20 May 2021 | 8,888 | 8,888 | - | - | Stock options (right to buy) | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 20 May 2021 | 1,585 | 1,585 | - | - | Restricted stock unit | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 22 Feb 2021 | 2,774 | 2,775 | - | - | Restricted stock units | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 22 Feb 2021 | 2,774 | 113,412 (0%) | 0% | 0 | Common stock | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 22 Feb 2021 | 821 | 112,591 (0%) | 0% | 0 | Common stock | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 16 Feb 2021 | 8,125 | 113,178 (0%) | 0% | 0 | Common stock | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 16 Feb 2021 | 8,125 | 0 | - | - | Restricted stock units | ||
| Agios Pharmaceuticals Inc | David P. Schenkein | Director | 16 Feb 2021 | 2,540 | 110,638 (0%) | 0% | 0 | Common stock | ||
| Denali Therapeutics Inc | David P. Schenkein | Director | Sale of securities on an exchange or to another person at price $ 90.06 per share. | 21 Dec 2020 | 25,000 | 0 (0%) | 0% | 90.1 | 2,251,555 | Common Stock |
| Denali Therapeutics Inc | David P. Schenkein | Director | Sale of securities on an exchange or to another person at price $ 90.01 per share. | 21 Dec 2020 | 5,000 | 26,232 (0%) | 0% | 90.0 | 450,027 | Common Stock |
| Denali Therapeutics Inc | David P. Schenkein | Director | Sale of securities on an exchange or to another person at price $ 70.05 per share. | 12 Nov 2020 | 30,000 | 25,000 (0%) | 0% | 70.1 | 2,101,590 | Common Stock |
| Denali Therapeutics Inc | David P. Schenkein | Director | Sale of securities on an exchange or to another person at price $ 60.03 per share. | 10 Nov 2020 | 10,000 | 55,000 (0%) | 0% | 60.0 | 600,310 | Common Stock |
| Denali Therapeutics Inc | David P. Schenkein | Director | Sale of securities on an exchange or to another person at price $ 50.18 per share. | 04 Nov 2020 | 10,000 | 65,000 (0%) | 0% | 50.2 | 501,830 | Common Stock |